New diabetes drug partnership

Tue, 28 Aug 2007
Two major diabetes drug companies, Pfizer and Bristol-Myers Squibb, are set to partner up to generate new medicines for diabetes and obesity. The established pharmaceutical companies now face considerable competition from other generic medicine.

The new collaboration will be centred around a set of compounds classed as DGAT-1 inhibitors. This family blocks the creation and storage of fat, and could play a principal role in the evolution of new medical treatments. Both companies are based in New York .

The business deal is expected to be a partnership, with Bristol paying Pfizer to research, and Pfizer fronting costs and getting greater profit share . City analysts take the partnership as a reaction against falling sales of major cash -generating drugs.
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.